Global Controlled Substance Market
Global Controlled Substance Market

Controlled Substance Comprehensive Study by Type (Opioids, Stimulants, Depressants, Cannabinoids), Treatment (Pain management, Sleep disorders, Depression and anxiety, Seizure, Attention Deficit Hyperactivity Disorder (ADHD), Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Controlled Substance Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 210 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Controlled Substance?
A controlled substance is a chemical or medicate that's firmly controlled by government. The utilize of controlled substance is regulated since it can cause sedate abuse or can be addictive. The making, handling, utilization, capacity & distribution of these substances is profoundly controlled by the Government. Such substances include opioids, depressants, hallucinogens, stimulants & steroids (anabolic). The controlled drugs utilized for therapeutic preparations require appropriate prescription from a authorized therapeutic professional. While morphine, Ritalin & Valium are the examples of legal controlled substances utilized for therapeutic reason, LSD and heroin are illegal. Some chemicals utilized for the production of illegal drugs are too controlled substances in many other nations. However they may lack pharmacological effects of the drugs.

The market study is broken down by Type (Opioids, Stimulants, Depressants and Cannabinoids) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition and changing of consumer spending patterns and need pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Controlled Substance market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-La Roche AG (Switzerland), AbbVie, Inc. (United States), Mallinckrodt plc (United Kingdom), Pfizer, Inc. (United States), Sun Pharmaceuticals Ltd. (India), Ampac Fine Chemicals (United States), GW Pharmaceuticals plc (United Kingdom) and Merck & Co., Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Lannett (United States) and Teva Pharmaceutical Ltd. (Israel).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Controlled Substance market by Type, Application and Region.

On the basis of geography, the market of Controlled Substance has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Pain management will boost the Controlled Substance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Controlled Substance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.


Manufacturers & suppliers of these drugs require a prior registration with the Drug Enforcement Agency (DEA)

Market Trend
  • Increased R&D Activities by Pharmaceutical Companies

Market Drivers
  • Increasing Chronic Pain Among the Geriatric Population
  • Favoring Policies by Government for Development

Opportunities
  • The Increasing Rate of ADHD (Attention Deficit Hyperactivity Disorder) among Children

Restraints
  • Lack of Awareness of Controlled Substance
  • High Prevalence of Illicit Controlled Substances
  • Extreme Side-Effects of Drugs

Challenges
  • High Predominance of Illicit Controlled Substances has Created Raw Material Shortage


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Controlled Substance Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as F. Hoffmann-La Roche AG (Switzerland), AbbVie, Inc. (United States), Mallinckrodt plc (United Kingdom), Pfizer, Inc. (United States), Sun Pharmaceuticals Ltd. (India), Ampac Fine Chemicals (United States), GW Pharmaceuticals plc (United Kingdom) and Merck & Co., Inc. (United States) etc.

2. What would be the Market Size of Controlled Substance Market by 2026?
Analysts at AMA estimates Controlled Substance Market to reach USDXXX by 2026.

3. Can we have customized study for Controlled Substance Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Report Objectives / Segmentation Covered
By Type
  • Opioids
  • Stimulants
  • Depressants
  • Cannabinoids
By Treatment
  • Pain management
  • Sleep disorders
  • Depression and anxiety
  • Seizure
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Chronic Pain Among the Geriatric Population
      • 3.2.2. Favoring Policies by Government for Development
    • 3.3. Market Challenges
      • 3.3.1. High Predominance of Illicit Controlled Substances has Created Raw Material Shortage
    • 3.4. Market Trends
      • 3.4.1. Increased R&D Activities by Pharmaceutical Companies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Controlled Substance, by Type, Treatment, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Controlled Substance (Value)
      • 5.2.1. Global Controlled Substance by: Type (Value)
        • 5.2.1.1. Opioids
        • 5.2.1.2. Stimulants
        • 5.2.1.3. Depressants
        • 5.2.1.4. Cannabinoids
      • 5.2.2. Global Controlled Substance by: Treatment (Value)
        • 5.2.2.1. Pain management
        • 5.2.2.2. Sleep disorders
        • 5.2.2.3. Depression and anxiety
        • 5.2.2.4. Seizure
        • 5.2.2.5. Attention Deficit Hyperactivity Disorder (ADHD)
        • 5.2.2.6. Others
      • 5.2.3. Global Controlled Substance by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Controlled Substance Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Controlled Substance (Volume)
      • 5.3.1. Global Controlled Substance by: Type (Volume)
        • 5.3.1.1. Opioids
        • 5.3.1.2. Stimulants
        • 5.3.1.3. Depressants
        • 5.3.1.4. Cannabinoids
      • 5.3.2. Global Controlled Substance by: Treatment (Volume)
        • 5.3.2.1. Pain management
        • 5.3.2.2. Sleep disorders
        • 5.3.2.3. Depression and anxiety
        • 5.3.2.4. Seizure
        • 5.3.2.5. Attention Deficit Hyperactivity Disorder (ADHD)
        • 5.3.2.6. Others
      • 5.3.3. Global Controlled Substance by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Controlled Substance Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Controlled Substance (Price)
      • 5.4.1. Global Controlled Substance by: Type (Price)
  • 6. Controlled Substance: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AbbVie, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mallinckrodt plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharmaceuticals Ltd. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ampac Fine Chemicals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GW Pharmaceuticals plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Controlled Substance Sale, by Type, Treatment, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Controlled Substance (Value)
      • 7.2.1. Global Controlled Substance by: Type (Value)
        • 7.2.1.1. Opioids
        • 7.2.1.2. Stimulants
        • 7.2.1.3. Depressants
        • 7.2.1.4. Cannabinoids
      • 7.2.2. Global Controlled Substance by: Treatment (Value)
        • 7.2.2.1. Pain management
        • 7.2.2.2. Sleep disorders
        • 7.2.2.3. Depression and anxiety
        • 7.2.2.4. Seizure
        • 7.2.2.5. Attention Deficit Hyperactivity Disorder (ADHD)
        • 7.2.2.6. Others
      • 7.2.3. Global Controlled Substance by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Controlled Substance Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Controlled Substance (Volume)
      • 7.3.1. Global Controlled Substance by: Type (Volume)
        • 7.3.1.1. Opioids
        • 7.3.1.2. Stimulants
        • 7.3.1.3. Depressants
        • 7.3.1.4. Cannabinoids
      • 7.3.2. Global Controlled Substance by: Treatment (Volume)
        • 7.3.2.1. Pain management
        • 7.3.2.2. Sleep disorders
        • 7.3.2.3. Depression and anxiety
        • 7.3.2.4. Seizure
        • 7.3.2.5. Attention Deficit Hyperactivity Disorder (ADHD)
        • 7.3.2.6. Others
      • 7.3.3. Global Controlled Substance by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Controlled Substance Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Controlled Substance (Price)
      • 7.4.1. Global Controlled Substance by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Controlled Substance: by Type(USD Million)
  • Table 2. Controlled Substance Opioids , by Region USD Million (2015-2020)
  • Table 3. Controlled Substance Stimulants , by Region USD Million (2015-2020)
  • Table 4. Controlled Substance Depressants , by Region USD Million (2015-2020)
  • Table 5. Controlled Substance Cannabinoids , by Region USD Million (2015-2020)
  • Table 6. Controlled Substance: by Treatment(USD Million)
  • Table 7. Controlled Substance Pain management , by Region USD Million (2015-2020)
  • Table 8. Controlled Substance Sleep disorders , by Region USD Million (2015-2020)
  • Table 9. Controlled Substance Depression and anxiety , by Region USD Million (2015-2020)
  • Table 10. Controlled Substance Seizure , by Region USD Million (2015-2020)
  • Table 11. Controlled Substance Attention Deficit Hyperactivity Disorder (ADHD) , by Region USD Million (2015-2020)
  • Table 12. Controlled Substance Others , by Region USD Million (2015-2020)
  • Table 13. Controlled Substance: by Distribution Channel(USD Million)
  • Table 14. Controlled Substance Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Controlled Substance Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Controlled Substance Online Pharmacies , by Region USD Million (2015-2020)
  • Table 17. South America Controlled Substance, by Country USD Million (2015-2020)
  • Table 18. South America Controlled Substance, by Type USD Million (2015-2020)
  • Table 19. South America Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 20. South America Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Controlled Substance, by Type USD Million (2015-2020)
  • Table 22. Brazil Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 23. Brazil Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 24. Argentina Controlled Substance, by Type USD Million (2015-2020)
  • Table 25. Argentina Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 26. Argentina Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 27. Rest of South America Controlled Substance, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 29. Rest of South America Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 30. Asia Pacific Controlled Substance, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Controlled Substance, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 33. Asia Pacific Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 34. China Controlled Substance, by Type USD Million (2015-2020)
  • Table 35. China Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 36. China Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 37. Japan Controlled Substance, by Type USD Million (2015-2020)
  • Table 38. Japan Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 39. Japan Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 40. India Controlled Substance, by Type USD Million (2015-2020)
  • Table 41. India Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 42. India Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 43. South Korea Controlled Substance, by Type USD Million (2015-2020)
  • Table 44. South Korea Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 45. South Korea Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 46. Taiwan Controlled Substance, by Type USD Million (2015-2020)
  • Table 47. Taiwan Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 48. Taiwan Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 49. Australia Controlled Substance, by Type USD Million (2015-2020)
  • Table 50. Australia Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 51. Australia Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Controlled Substance, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 55. Europe Controlled Substance, by Country USD Million (2015-2020)
  • Table 56. Europe Controlled Substance, by Type USD Million (2015-2020)
  • Table 57. Europe Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 58. Europe Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 59. Germany Controlled Substance, by Type USD Million (2015-2020)
  • Table 60. Germany Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 61. Germany Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 62. France Controlled Substance, by Type USD Million (2015-2020)
  • Table 63. France Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 64. France Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 65. Italy Controlled Substance, by Type USD Million (2015-2020)
  • Table 66. Italy Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 67. Italy Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 68. United Kingdom Controlled Substance, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 70. United Kingdom Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 71. Netherlands Controlled Substance, by Type USD Million (2015-2020)
  • Table 72. Netherlands Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 73. Netherlands Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 74. Rest of Europe Controlled Substance, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 76. Rest of Europe Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 77. MEA Controlled Substance, by Country USD Million (2015-2020)
  • Table 78. MEA Controlled Substance, by Type USD Million (2015-2020)
  • Table 79. MEA Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 80. MEA Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 81. Middle East Controlled Substance, by Type USD Million (2015-2020)
  • Table 82. Middle East Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 83. Middle East Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 84. Africa Controlled Substance, by Type USD Million (2015-2020)
  • Table 85. Africa Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 86. Africa Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 87. North America Controlled Substance, by Country USD Million (2015-2020)
  • Table 88. North America Controlled Substance, by Type USD Million (2015-2020)
  • Table 89. North America Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 90. North America Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 91. United States Controlled Substance, by Type USD Million (2015-2020)
  • Table 92. United States Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 93. United States Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 94. Canada Controlled Substance, by Type USD Million (2015-2020)
  • Table 95. Canada Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 96. Canada Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 97. Mexico Controlled Substance, by Type USD Million (2015-2020)
  • Table 98. Mexico Controlled Substance, by Treatment USD Million (2015-2020)
  • Table 99. Mexico Controlled Substance, by Distribution Channel USD Million (2015-2020)
  • Table 100. Controlled Substance Sales: by Type(K Units)
  • Table 101. Controlled Substance Sales Opioids , by Region K Units (2015-2020)
  • Table 102. Controlled Substance Sales Stimulants , by Region K Units (2015-2020)
  • Table 103. Controlled Substance Sales Depressants , by Region K Units (2015-2020)
  • Table 104. Controlled Substance Sales Cannabinoids , by Region K Units (2015-2020)
  • Table 105. Controlled Substance Sales: by Treatment(K Units)
  • Table 106. Controlled Substance Sales Pain management , by Region K Units (2015-2020)
  • Table 107. Controlled Substance Sales Sleep disorders , by Region K Units (2015-2020)
  • Table 108. Controlled Substance Sales Depression and anxiety , by Region K Units (2015-2020)
  • Table 109. Controlled Substance Sales Seizure , by Region K Units (2015-2020)
  • Table 110. Controlled Substance Sales Attention Deficit Hyperactivity Disorder (ADHD) , by Region K Units (2015-2020)
  • Table 111. Controlled Substance Sales Others , by Region K Units (2015-2020)
  • Table 112. Controlled Substance Sales: by Distribution Channel(K Units)
  • Table 113. Controlled Substance Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 114. Controlled Substance Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 115. Controlled Substance Sales Online Pharmacies , by Region K Units (2015-2020)
  • Table 116. South America Controlled Substance Sales, by Country K Units (2015-2020)
  • Table 117. South America Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 118. South America Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 119. South America Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 120. Brazil Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 121. Brazil Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 122. Brazil Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 123. Argentina Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 124. Argentina Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 125. Argentina Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 126. Rest of South America Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 127. Rest of South America Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 128. Rest of South America Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 129. Asia Pacific Controlled Substance Sales, by Country K Units (2015-2020)
  • Table 130. Asia Pacific Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 131. Asia Pacific Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 132. Asia Pacific Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 133. China Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 134. China Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 135. China Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 136. Japan Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 137. Japan Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 138. Japan Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 139. India Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 140. India Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 141. India Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 142. South Korea Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 143. South Korea Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 144. South Korea Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 145. Taiwan Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 146. Taiwan Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 147. Taiwan Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 148. Australia Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 149. Australia Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 150. Australia Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 151. Rest of Asia-Pacific Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 152. Rest of Asia-Pacific Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 153. Rest of Asia-Pacific Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 154. Europe Controlled Substance Sales, by Country K Units (2015-2020)
  • Table 155. Europe Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 156. Europe Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 157. Europe Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 158. Germany Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 159. Germany Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 160. Germany Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 161. France Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 162. France Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 163. France Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 164. Italy Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 165. Italy Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 166. Italy Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 167. United Kingdom Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 168. United Kingdom Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 169. United Kingdom Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 170. Netherlands Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 171. Netherlands Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 172. Netherlands Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. Rest of Europe Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 174. Rest of Europe Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 175. Rest of Europe Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 176. MEA Controlled Substance Sales, by Country K Units (2015-2020)
  • Table 177. MEA Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 178. MEA Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 179. MEA Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 180. Middle East Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 181. Middle East Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 182. Middle East Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 183. Africa Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 184. Africa Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 185. Africa Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 186. North America Controlled Substance Sales, by Country K Units (2015-2020)
  • Table 187. North America Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 188. North America Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 189. North America Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 190. United States Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 191. United States Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 192. United States Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 193. Canada Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 194. Canada Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 195. Canada Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 196. Mexico Controlled Substance Sales, by Type K Units (2015-2020)
  • Table 197. Mexico Controlled Substance Sales, by Treatment K Units (2015-2020)
  • Table 198. Mexico Controlled Substance Sales, by Distribution Channel K Units (2015-2020)
  • Table 199. Controlled Substance: by Type(USD/Units)
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Controlled Substance: by Type(USD Million)
  • Table 209. Controlled Substance Opioids , by Region USD Million (2021-2026)
  • Table 210. Controlled Substance Stimulants , by Region USD Million (2021-2026)
  • Table 211. Controlled Substance Depressants , by Region USD Million (2021-2026)
  • Table 212. Controlled Substance Cannabinoids , by Region USD Million (2021-2026)
  • Table 213. Controlled Substance: by Treatment(USD Million)
  • Table 214. Controlled Substance Pain management , by Region USD Million (2021-2026)
  • Table 215. Controlled Substance Sleep disorders , by Region USD Million (2021-2026)
  • Table 216. Controlled Substance Depression and anxiety , by Region USD Million (2021-2026)
  • Table 217. Controlled Substance Seizure , by Region USD Million (2021-2026)
  • Table 218. Controlled Substance Attention Deficit Hyperactivity Disorder (ADHD) , by Region USD Million (2021-2026)
  • Table 219. Controlled Substance Others , by Region USD Million (2021-2026)
  • Table 220. Controlled Substance: by Distribution Channel(USD Million)
  • Table 221. Controlled Substance Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 222. Controlled Substance Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 223. Controlled Substance Online Pharmacies , by Region USD Million (2021-2026)
  • Table 224. South America Controlled Substance, by Country USD Million (2021-2026)
  • Table 225. South America Controlled Substance, by Type USD Million (2021-2026)
  • Table 226. South America Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 227. South America Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 228. Brazil Controlled Substance, by Type USD Million (2021-2026)
  • Table 229. Brazil Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 230. Brazil Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 231. Argentina Controlled Substance, by Type USD Million (2021-2026)
  • Table 232. Argentina Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 233. Argentina Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 234. Rest of South America Controlled Substance, by Type USD Million (2021-2026)
  • Table 235. Rest of South America Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 236. Rest of South America Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 237. Asia Pacific Controlled Substance, by Country USD Million (2021-2026)
  • Table 238. Asia Pacific Controlled Substance, by Type USD Million (2021-2026)
  • Table 239. Asia Pacific Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 240. Asia Pacific Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 241. China Controlled Substance, by Type USD Million (2021-2026)
  • Table 242. China Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 243. China Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 244. Japan Controlled Substance, by Type USD Million (2021-2026)
  • Table 245. Japan Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 246. Japan Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 247. India Controlled Substance, by Type USD Million (2021-2026)
  • Table 248. India Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 249. India Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 250. South Korea Controlled Substance, by Type USD Million (2021-2026)
  • Table 251. South Korea Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 252. South Korea Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 253. Taiwan Controlled Substance, by Type USD Million (2021-2026)
  • Table 254. Taiwan Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 255. Taiwan Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 256. Australia Controlled Substance, by Type USD Million (2021-2026)
  • Table 257. Australia Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 258. Australia Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 259. Rest of Asia-Pacific Controlled Substance, by Type USD Million (2021-2026)
  • Table 260. Rest of Asia-Pacific Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 261. Rest of Asia-Pacific Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 262. Europe Controlled Substance, by Country USD Million (2021-2026)
  • Table 263. Europe Controlled Substance, by Type USD Million (2021-2026)
  • Table 264. Europe Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 265. Europe Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 266. Germany Controlled Substance, by Type USD Million (2021-2026)
  • Table 267. Germany Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 268. Germany Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 269. France Controlled Substance, by Type USD Million (2021-2026)
  • Table 270. France Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 271. France Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 272. Italy Controlled Substance, by Type USD Million (2021-2026)
  • Table 273. Italy Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 274. Italy Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 275. United Kingdom Controlled Substance, by Type USD Million (2021-2026)
  • Table 276. United Kingdom Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 277. United Kingdom Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 278. Netherlands Controlled Substance, by Type USD Million (2021-2026)
  • Table 279. Netherlands Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 280. Netherlands Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 281. Rest of Europe Controlled Substance, by Type USD Million (2021-2026)
  • Table 282. Rest of Europe Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 283. Rest of Europe Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 284. MEA Controlled Substance, by Country USD Million (2021-2026)
  • Table 285. MEA Controlled Substance, by Type USD Million (2021-2026)
  • Table 286. MEA Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 287. MEA Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 288. Middle East Controlled Substance, by Type USD Million (2021-2026)
  • Table 289. Middle East Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 290. Middle East Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 291. Africa Controlled Substance, by Type USD Million (2021-2026)
  • Table 292. Africa Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 293. Africa Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 294. North America Controlled Substance, by Country USD Million (2021-2026)
  • Table 295. North America Controlled Substance, by Type USD Million (2021-2026)
  • Table 296. North America Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 297. North America Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 298. United States Controlled Substance, by Type USD Million (2021-2026)
  • Table 299. United States Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 300. United States Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 301. Canada Controlled Substance, by Type USD Million (2021-2026)
  • Table 302. Canada Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 303. Canada Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 304. Mexico Controlled Substance, by Type USD Million (2021-2026)
  • Table 305. Mexico Controlled Substance, by Treatment USD Million (2021-2026)
  • Table 306. Mexico Controlled Substance, by Distribution Channel USD Million (2021-2026)
  • Table 307. Controlled Substance Sales: by Type(K Units)
  • Table 308. Controlled Substance Sales Opioids , by Region K Units (2021-2026)
  • Table 309. Controlled Substance Sales Stimulants , by Region K Units (2021-2026)
  • Table 310. Controlled Substance Sales Depressants , by Region K Units (2021-2026)
  • Table 311. Controlled Substance Sales Cannabinoids , by Region K Units (2021-2026)
  • Table 312. Controlled Substance Sales: by Treatment(K Units)
  • Table 313. Controlled Substance Sales Pain management , by Region K Units (2021-2026)
  • Table 314. Controlled Substance Sales Sleep disorders , by Region K Units (2021-2026)
  • Table 315. Controlled Substance Sales Depression and anxiety , by Region K Units (2021-2026)
  • Table 316. Controlled Substance Sales Seizure , by Region K Units (2021-2026)
  • Table 317. Controlled Substance Sales Attention Deficit Hyperactivity Disorder (ADHD) , by Region K Units (2021-2026)
  • Table 318. Controlled Substance Sales Others , by Region K Units (2021-2026)
  • Table 319. Controlled Substance Sales: by Distribution Channel(K Units)
  • Table 320. Controlled Substance Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 321. Controlled Substance Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 322. Controlled Substance Sales Online Pharmacies , by Region K Units (2021-2026)
  • Table 323. South America Controlled Substance Sales, by Country K Units (2021-2026)
  • Table 324. South America Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 325. South America Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 326. South America Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 327. Brazil Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 328. Brazil Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 329. Brazil Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 330. Argentina Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 331. Argentina Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 332. Argentina Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 333. Rest of South America Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 334. Rest of South America Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 335. Rest of South America Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 336. Asia Pacific Controlled Substance Sales, by Country K Units (2021-2026)
  • Table 337. Asia Pacific Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 338. Asia Pacific Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 339. Asia Pacific Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 340. China Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 341. China Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 342. China Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 343. Japan Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 344. Japan Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 345. Japan Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 346. India Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 347. India Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 348. India Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 349. South Korea Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 350. South Korea Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 351. South Korea Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 352. Taiwan Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 353. Taiwan Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 354. Taiwan Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 355. Australia Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 356. Australia Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 357. Australia Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 358. Rest of Asia-Pacific Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 359. Rest of Asia-Pacific Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 360. Rest of Asia-Pacific Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 361. Europe Controlled Substance Sales, by Country K Units (2021-2026)
  • Table 362. Europe Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 363. Europe Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 364. Europe Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 365. Germany Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 366. Germany Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 367. Germany Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 368. France Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 369. France Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 370. France Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 371. Italy Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 372. Italy Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 373. Italy Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 374. United Kingdom Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 375. United Kingdom Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 376. United Kingdom Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 377. Netherlands Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 378. Netherlands Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 379. Netherlands Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 380. Rest of Europe Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 381. Rest of Europe Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 382. Rest of Europe Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 383. MEA Controlled Substance Sales, by Country K Units (2021-2026)
  • Table 384. MEA Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 385. MEA Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 386. MEA Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 387. Middle East Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 388. Middle East Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 389. Middle East Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 390. Africa Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 391. Africa Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 392. Africa Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 393. North America Controlled Substance Sales, by Country K Units (2021-2026)
  • Table 394. North America Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 395. North America Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 396. North America Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 397. United States Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 398. United States Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 399. United States Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 400. Canada Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 401. Canada Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 402. Canada Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 403. Mexico Controlled Substance Sales, by Type K Units (2021-2026)
  • Table 404. Mexico Controlled Substance Sales, by Treatment K Units (2021-2026)
  • Table 405. Mexico Controlled Substance Sales, by Distribution Channel K Units (2021-2026)
  • Table 406. Controlled Substance: by Type(USD/Units)
  • Table 407. Research Programs/Design for This Report
  • Table 408. Key Data Information from Secondary Sources
  • Table 409. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Controlled Substance: by Type USD Million (2015-2020)
  • Figure 5. Global Controlled Substance: by Treatment USD Million (2015-2020)
  • Figure 6. Global Controlled Substance: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Controlled Substance Share (%), by Country
  • Figure 8. Asia Pacific Controlled Substance Share (%), by Country
  • Figure 9. Europe Controlled Substance Share (%), by Country
  • Figure 10. MEA Controlled Substance Share (%), by Country
  • Figure 11. North America Controlled Substance Share (%), by Country
  • Figure 12. Global Controlled Substance: by Type K Units (2015-2020)
  • Figure 13. Global Controlled Substance: by Treatment K Units (2015-2020)
  • Figure 14. Global Controlled Substance: by Distribution Channel K Units (2015-2020)
  • Figure 15. South America Controlled Substance Share (%), by Country
  • Figure 16. Asia Pacific Controlled Substance Share (%), by Country
  • Figure 17. Europe Controlled Substance Share (%), by Country
  • Figure 18. MEA Controlled Substance Share (%), by Country
  • Figure 19. North America Controlled Substance Share (%), by Country
  • Figure 20. Global Controlled Substance: by Type USD/Units (2015-2020)
  • Figure 21. Global Controlled Substance share by Players 2020 (%)
  • Figure 22. Global Controlled Substance share by Players (Top 3) 2020(%)
  • Figure 23. Global Controlled Substance share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Mallinckrodt plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Mallinckrodt plc (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Sun Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 34. Sun Pharmaceuticals Ltd. (India) Revenue: by Geography 2020
  • Figure 35. Ampac Fine Chemicals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Ampac Fine Chemicals (United States) Revenue: by Geography 2020
  • Figure 37. GW Pharmaceuticals plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GW Pharmaceuticals plc (United Kingdom) Revenue: by Geography 2020
  • Figure 39. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Global Controlled Substance: by Type USD Million (2021-2026)
  • Figure 42. Global Controlled Substance: by Treatment USD Million (2021-2026)
  • Figure 43. Global Controlled Substance: by Distribution Channel USD Million (2021-2026)
  • Figure 44. South America Controlled Substance Share (%), by Country
  • Figure 45. Asia Pacific Controlled Substance Share (%), by Country
  • Figure 46. Europe Controlled Substance Share (%), by Country
  • Figure 47. MEA Controlled Substance Share (%), by Country
  • Figure 48. North America Controlled Substance Share (%), by Country
  • Figure 49. Global Controlled Substance: by Type K Units (2021-2026)
  • Figure 50. Global Controlled Substance: by Treatment K Units (2021-2026)
  • Figure 51. Global Controlled Substance: by Distribution Channel K Units (2021-2026)
  • Figure 52. South America Controlled Substance Share (%), by Country
  • Figure 53. Asia Pacific Controlled Substance Share (%), by Country
  • Figure 54. Europe Controlled Substance Share (%), by Country
  • Figure 55. MEA Controlled Substance Share (%), by Country
  • Figure 56. North America Controlled Substance Share (%), by Country
  • Figure 57. Global Controlled Substance: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-La Roche AG (Switzerland)
  • AbbVie, Inc. (United States)
  • Mallinckrodt plc (United Kingdom)
  • Pfizer, Inc. (United States)
  • Sun Pharmaceuticals Ltd. (India)
  • Ampac Fine Chemicals (United States)
  • GW Pharmaceuticals plc (United Kingdom)
  • Merck & Co., Inc. (United States)
Additional players considered in the study are as follows:
Lannett (United States) , Teva Pharmaceutical Ltd. (Israel)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation